Anti-Rift Valley Fever Virus, Glycoprotein (Gc) (Clone RVFV-250) -Purified No Carrier Protein

Specificity: Clone RVFV-250 binds to a region of domain II (DII) adjacent to the fusion loop of the Gc glycoprotein of Rift Valley Fever Virus (RVFV) . Antigen Distribution: RVFV is primarily found in hepatic cells, endothelial cells, and mononuclear phagocytes in the human body. This distribution reflects the virus's tendency to cause hepatitis, hemorrhagic fever, and encephalitis during infection. Background: RVFV is a mosquito-borne phlebovirus primarily found in sub-Saharan Africa, especially in eastern and southern Africa. It infects both humans and ungulates (such as cows, goats, and sheep) . RVFV causes a wide range of health effects, from mild illness to severe conditions like hemorrhagic disease, encephalitis, hepatitis, kidney injury, and retinitis. The virus can lead to spontaneous abortions in animals. RVFV outbreaks often occur during years of unusually heavy rainfall and flooding, as mosquitoes hatch more eggs, increasing transmission potential1,2. RVFV-250 targets the Gc protein of RVFV. It has an IC50 value of 51 ng/mL for the MP-12 vaccine strain, indicating moderate neutralizing activity. However, it shows reduced neutralization potency against wild-type strains and SA51, with IC50 values of 120 ng/mL. RVFV-250 binds to specific regions on the Gc protein, contributing to its ability to neutralize the virus3.